Aviv Biomedical is in the final period of its NIH funded SBIR Phase II grant (5R44EB015924-03), awarded for the development of the bilirubin hematofluorometer. Beta instruments have been made and placed into research at multiple hospitals. Publications are in progress.The results were in excellent agreement with past versions of this instrument, and correlates were drawn to existing methodologies.1, 2
Aviv is now in the process of expanding research to additional facilities. Additional research funding will be sought to aid with demonstration of the technique’s usefulness, and to develop the device’s final form.
Neonatal hyperbilirubinemia and jaundice occur in almost all newborns and may be benign if its progression to extreme hyperbilirubinemia is recognized, monitored, and prevented or managed in a timely manner.3 It is our hope that the hematofluorometer will be able to provide aid with the more accurate and faster diagnosis of hyperbilirubinemia.
1 Lamola AA, Fanaroff AA. “Bilirubin fluorescence and prevention of kernicterus.” (1984) Diagn Med 7:9-12
2 Accepted for publication
3 Bhutani, V. K., A. Zipursky, H. Blencowe, R. Khanna, M. Sgro, F. Ebbesen, J. Bell, R. Mori, T. M. Slusher, N. Fahmy, V. K. Paul, L. Du, A. A. Okolo, M.-F. d. Almeida, B. O. Olusanya, P. Kumar, S. Cousens and J. E. Lawn (2013) “Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.” Pediatric Research 74(S1): 86-100
Research reported in this press release was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number R44EB015924. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.